



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR UNITS OR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



INVICTA DIAGNOSTIC LIMITED

Our Company was incorporated as Limited Liability Partnership under the name “*Invicta Diagnostic LLP*” under the provisions of the Limited Liability Partnership Act, 2008 vide Certificate of Incorporation dated January 22, 2021 issued by Assistant Registrar of Companies, Central Registration Centre. Further, Invicta Diagnostic LLP was converted into a private limited company “*Invicta Diagnostic Private Limited*” pursuant to the provisions of Chapter XXI of the Companies Act, 2013 and a fresh Certificate of Incorporation dated December 01, 2023 was issued by Assistant Registrar of Companies, Central Registration Centre. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of our Shareholders held on April 20, 2024 and the name of our Company was changed to “*Invicta Diagnostic Limited*” and a fresh certificate of incorporation dated July 02, 2024 was issued to our Company by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. The Corporate Identification Number of our Company is U86100MH2023PLC414723. For further details on incorporation and registered office of our Company, see “*History and Certain Corporate Matters*” on page 194 of the DRHP.

Corporate Identification Number: U86100MH2023PLC414723;

Registered Office: 1 GF, Plot 217, Ambavat Bhavan, N.M Joshi Marg, Delisle Road, Mumbai – 400 013, Maharashtra, India;

Corporate Office: Office No. 1012, 10th Floor, Hubtown Viva CHS Ltd, Western Express Highway, Mogra Village, Near Shankar Wadi, Jogeshwari East, Mumbai – 400 060, Maharashtra, India;

Contact Person: Soniya Nilesh Mahajan, Company Secretary and Compliance Officer;

Telephone: 022 - 4971 0036; **Email:** investors@pcdiagnostics.in; **Website:** www.pcdiagnostics.in

THE PROMOTERS OF OUR COMPANY ARE DR. KETAN JAYANTILAL JAIN, DR. SANKET VINOD JAIN, ROHIT PRAKASH SRIVASTAVA, BADAL KAILASH NAREDI AND JAYESH PRAKASH JAIN

ADDENDUM TO THE DRAFT RED HERRING PROSPECTUS DATED JULY 04, 2025 NOTICE TO THE INVESTORS (“THE ADDENDUM”)

INITIAL PUBLIC OFFERING OF UPTO 33,08,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (“EQUITY SHARES”) FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ [●] PER EQUITY SHARE) (“ISSUE PRICE”) AGGREGATING TO ₹ [●] LAKHS (“THE ISSUE”). THE ISSUE WILL CONSTITUTE [●] % OF THE POST-ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE ISSUE INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES AGGREGATING TO ₹ [●] LAKHS (CONSTITUTING UP TO [●] % OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY MARKET MAKER (“MARKET MAKER RESERVATION PORTION”). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE “NET ISSUE”. THE ISSUE AND THE NET ISSUE WILL CONSTITUTE [●] % AND [●] % RESPECTIVELY, OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

Potential investor may note the following:

1. The section titled “*Risk Factors*” beginning on page 41 of the Draft Red Herring Prospectus has been revised and updated as suggested by the NSE.
2. The content of “*Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra*” under the heading “*Details of the Objects*” under the chapter titled “*Objects of the Issue*” under the Section V titled “*Particulars of the Issue*” beginning on page 98 of the Draft Red Herring Prospectus has been updated as suggested by the NSE.
3. The content of “*Our Operational Network*”, “*Suppliers and Operational Procurement*” has been added as suggested by the NSE and the content of “*Our Customers*”, “*Human Resources*” and “*Properties*” has been updated as suggested by the NSE under the chapter titled “*Our Business*” beginning on page 162 of the Draft Red Herring Prospectus.
4. The content of “*Brief Profile of our Directors*”, “*Changes to our Board in the last three years*” and “*Changes in the Key Managerial Personnel or the Senior Management in last three years*” under the chapter titled “*Our Management*” beginning on page 202 of the Draft Red Herring Prospectus has been updated as suggested by the NSE.
5. The content of “*Litigation involving our Promoters*” under the chapter titled “*Outstanding Litigation and Material Developments*” beginning on page 254 of the Draft Red Herring Prospectus has been updated as suggested by the NSE.
6. The content of “*Eligibility for the Issue*” under the section titled “*Other Regulatory and Statutory Disclosures*” beginning on page 276 of the Draft Red Herring Prospectus has been updated as suggested by NSE.

The above is to be read in conjunction with the Draft Red Herring Prospectus and accordingly their references in the Draft Red Herring Prospectus stand amended pursuant to this Addendum. Please note that the changes pursuant to this Addendum will be appropriately included in the Red Herring Prospectus, as and when filed with the RoC, the SEBI and the Stock Exchange. All capitalised terms used in this Addendum shall, unless the context otherwise requires, have the meaning ascribed to them in the Draft Red Herring Prospectus.

On behalf of Invicta Diagnostic Limited

Place: Mumbai
Date: August 23, 2025

Sd/-
Dr. Sanket Vinod Jain
Chairman and Non-Executive Director

BOOK RUNNING LEAD MANAGER (“BRLM”)

REGISTRAR TO THE ISSUE



SOCRADAMUS CAPITAL PRIVATE LIMITED
Gala No. 303, Cama Industrial Estate, Sun Mill Compound, Delisle Road, Lower Parel (West), Mumbai – 400 013, Maharashtra, India
Telephone: 022 – 4961 4235
Email: info@socradamus.in
Investors Grievance e-mail: investors@socradamus.in
Website: https://socradamus.in/
Contact Person: Kritika Rupda
SEBI Registration Number: INM000013138

BIGSHARE SERVICES PRIVATE LIMITED
Office No. S6-2, 6th Floor, Pinnacle Business Park, next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai – 400 093, Maharashtra, India
Telephone: 022 - 6263 8200
Email: ipo@bigshareonline.com
Investor Grievance e-mail: investor@bigshareonline.com
Website: www.bigshareonline.com
Contact Person: Babu Rapheal C
SEBI Registration Number: INR000001385

BID / ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE	[●]**	BID / ISSUE OPENS ON	[●]	BID / ISSUE CLOSING ON	[●]***
------------------------------	-------	----------------------	-----	------------------------	--------

Our Company in consultation with the BRLM, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid / Issue Opening Date.

*** Our Company in consultation with the BRLM, may consider closing the Bid / Issue Period for QIBs one Working Day prior to the Bid / Issue Closing Date in accordance with the SEBI ICDR Regulations.

The UPI mandate end time and date shall be at 5:00 p.m. on Bid / Issue Closing Date.

Table of Contents

SECTION III – RISK FACTORS	3
SECTION V – PARTICULARS OF THE ISSUE.....	7
OBJECTS OF THE ISSUE.....	7
SECTION VI – ABOUT THE COMPANY	8
OUR BUSINESS	8
SECTION VI – ABOUT THE COMPANY	11
OUR MANAGEMENT.....	11
SECTION VIII – LEGAL AND OTHER INFORMATION	12
OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS.....	12
SECTION X - OTHER REGULATORY AND STATUTORY DISCLOSURES	13

SECTION III – RISK FACTORS

Risk Factor (Old reference)	Risk Factor (New Reference)	Changes
1	1	No change
2	2	Risk Factor has been updated <i>Any interruptions at our flagship centre and other diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.</i> Our flagship centre, which is located in Thane, Maharashtra, is our main ‘hub’ and equipped to conduct majority of the tests offered by us. In addition to walk-in patients, our flagship centre also receives test requests and related specimens from certain other diagnostic centres in our network. Consequently, if we experience any interruptions at our flagship centre, or if it fails to function, in whole or in part, because of events such as a fire, natural disaster or a loss of licenses, certifications or permits or other reasons or events beyond our control, our services at such diagnostic centre may be adversely affected or suspended. Further, there are certain tests that we only perform at our flagship centre. As a result, the occurrence of such events could also cause us to lose our patients and we may face significant increase in costs for test processing, transport and logistics which we may not be able to pass on to our patients. Any failure, malfunction, shutdown or partial or complete destruction of our flagship centre could adversely affect our business, prospects, results of operations and financial condition. Additionally, we have 3 hub centres through our subsidiaries, which are equipped to conduct all of pathology specimens’ collection, basic radiology tests and certain advanced radiology tests. Any interruptions at these service centres or any failure in operating in whole or in part of these facilities may also adversely affect our business, results of operations and financial condition. Further, we have recently discontinued operations at Mazgaon centre after evaluating its commercial viability, and there is no assurance that similar decisions will not be taken for other centres in the future based on operational or financial considerations.
3-9	3-9	No changes
10	10	Risk Factor has been added <i>The industry in which we operate possess various risks and challenges as provided in the Industry Report titled “Industry Report on Diagnostic Industry in India” dated July 22, 2024, which is exclusively prepared for the purposes of the Offer and issued by D&B and is commissioned and paid for by our Company (“D&B Report”).</i> The Diagnostic Industry in which we operate possess various risks and challenges such as: • <i>Persistent Healthcare Infrastructure Gaps:</i> Despite the aggressive investments by the private sector and stepped-up government spending to improve the medical care infrastructure, the country still lags when compared with other developed nations and most of the developing countries in terms of healthcare infrastructure as well as healthcare workers. • <i>Rural Barriers:</i> The "Rural Health Statistics 2021-22" report by the Ministry of Health and Family Welfare highlights a critical shortage of the public health infrastructure and human resources especially in rural India. The lack of diagnostic infrastructure and healthcare manpower significantly impacts the diagnostic lab industry, especially in smaller cities, limiting clinical trials and diagnostic services, and restricting industry growth. This leads to reliance on larger cities for clinical trials and services, reducing the patient pool in smaller areas. Additionally, limited awareness and accessibility in rural and semi-urban regions further restrict the industry's growth. • <i>Shortfall in Health Facilities in Rural Areas:</i> As of FY 2022, Sub-Centres were at a shortfall of 48,060 (25%), followed by Primary Healthcare Centres at 9,742

Risk Factor (Old reference)	Risk Factor (New Reference)	Changes
		(31%) and Community Healthcare Centres at 2,852 (36%). <i>Shortfall of Diagnostic Infrastructure in Community Healthcare Centres in Rural Areas:</i> As of FY 2022, Community Healthcare Centres in rural areas required 5,480 radiographers, 5,480 X-ray machines, and 5,480 functional laboratories. However, there were only 2,448 radiographers, 3,168 X-ray machines, and 5,502 functional laboratories available, indicating significant shortfall. <i>Shortfall of Health Manpower in Sub-Centres & Primary Healthcare Centres in Rural Areas:</i> As of FY 2022, Female Health Workers were at a shortfall of 3.50%, Male Health Workers at 66.60% and Doctors at 3.10%, indicating significant shortfall. <i>Skilled Manpower Shortage:</i> The industry lacks availability of skilled professionals, especially in tier 2 and tier 3 cities and in rural areas, who can effectively collect and perform different types of diagnostic tests. Additionally, many standalone centers, especially in smaller towns and cities also lack professionals who could accurately read and analyze the diagnostic test results. This shortage in skilled manpower availability presents a serious constraint on overall market growth. These above challenges could have a material adverse effect on our business, financial condition, cash flow and results of operations.
10	12	No change
11	13	No change
12	14	No change
13	15	No change
14	16	No change
15	17	No change
16	18	No change
17	19	No change
18	20	No change
19	21	No change
20	22	No change
21	23	No change
22	24	No change
23	25	No change
24	26	No change
25	27	No change
26	28	No change
27	29	No change
28	30	No change
29	31	No change
30	32	No change
31	33	No change
32	34	No change
33	11	Risk Factor has been shifted <i>If we pursue strategic acquisitions, we may not be able to successfully consummate favourable transactions or successfully integrate acquired businesses.</i> From time to time, we may evaluate potential acquisitions that would further the strategic objectives of our Company. However, we may not be able to (i) identify or secure suitable investment or acquisition opportunities, or our competitors may capitalise on such opportunities before we do; (ii) obtain requisite approvals from governmental authorities on a timely basis; (iii) consummate a transaction without delay and on terms that are favourable to us; or (iv) achieve expected returns and other benefits as a result of integration challenges or anti-monopoly regulations. Further, companies or operations acquired by us may not be profitable and may have

Risk Factor (Old reference)	Risk Factor (New Reference)	Changes
		unidentified issues not discovered in our due diligence process including hidden liabilities and legal contingencies or may not achieve sales levels and profitability that justify the investments made. Our corporate development activities may entail financial and operational risks, including diversion of management attention and other resources from our existing core businesses, difficulty in integrating, retaining or separating personnel and financial and other systems, and negative impacts on existing business relationships with suppliers and customers, difficulty in maintaining standards among diagnostic centres in different regions and complexity of large-scale business operations. If we fail to successfully source, execute and integrate investments or acquisitions, we may have to discontinue the operations of acquired companies and write off our investments, and as a result our overall growth could be impaired, and our business, results of operations and financial condition could be adversely affected. Future acquisitions could also result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities and increased operating expenses, all of which could adversely affect our business, financial condition, results of operations and prospects.
34	35	No change
35	36	No change
36	37	Risk Factor has been updated <i>Our insurance coverage may not be sufficient or may not adequately protect us against all material hazards, which may adversely affect our business, results of operations and financial condition.</i> Our insurance coverage may not be sufficient or may not adequately protect us against all material hazards, which may adversely affect our business, results of operations and financial condition. The principal types of coverage under our insurance policies include fire and special perils policy, burglary policy, errors and omissions policy. The insurance coverage which we maintain is reasonably adequate to cover the normal risks associated with the operation of our businesses. Even if we have insurance for the incident giving rise to the loss, we may be required to pay a significant deductible on any claim for recovery of such a loss, or the amount of the loss may exceed our coverage for the loss. However, we cannot assure you that any claim under the insurance policies maintained by us will be honoured fully, in part or on time, or that we have obtained sufficient insurance to cover all our losses. In addition, our insurance coverage expires from time to time. We apply for the renewal of our insurance coverage in the normal course of our business, and while we have no reason to believe that we will not be able to renew our existing insurance coverage as and when such policies expire, or obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct our businesses as now conducted, we cannot assure you that such renewals will be granted in a timely manner, or at acceptable cost, or at all. To the extent that we suffer loss or damage, or successful assertion of one or more large claims against us for events for which we are not insured, or for which we did not obtain or maintain insurance, or which is not covered in full or part by insurance, exceeds our insurance coverage or where our insurance claims are rejected, the loss would have to be borne by us and our results of operations, financial condition and cash flows could be adversely affected. In past there has been no instance of claiming of insurance the company but we cannot assure you about the future claims. Further, our Company has secured multiple insurance policies to safeguard its assets and operations. Fire insurance coverage has been obtained from Bajaj Allianz General Insurance Company for three locations i.e. Byculla, Thane and Bhayander East with sums insured of ₹490.01 lakhs, ₹820.00 lakhs, and ₹246.22 lakhs respectively. An additional fire and burglary insurance policy for our registered office i.e. Parel unit from ICICI Lombard General Insurance Company provides coverage of ₹12.04 lakhs. Reliance General Insurance Company covers Marol (Andheri East) facility under a fire insurance policy with a sum insured of ₹430.00 lakhs. Furthermore, our Company has availed Errors and Omissions insurance from the Association of Medical Consultants (Mumbai) for three location i.e. for Thane, Marol (Andheri East) and Byculla with policies offering coverage of ₹50.00 lakhs respectively.

Risk Factor (Old reference)	Risk Factor (New Reference)	Changes
		We have not made any claims under our existing insurance policies to date. Accordingly, the adequacy and effectiveness of our insurance coverage remain untested, and there is no assurance that it will be sufficient to cover all potential losses or liabilities.
37	38	No change
38	39	No change
39	40	No change
40	41	No change
41	42	No change
42	43	No change
43	44	No change
44	45	No change
45	46	No change
46	47	No change
47	48	No change
48	49	No change
49	50	No change
50	51	No change
51	52	No change
52	53	No change
53	54	No change
54	55	No change
55	56	No change
56	57	No change
57	58	No change
58	59	No change
59	60	No change
60	61	No change
61	62	No change
62	63	No change
63	64	No change

SECTION V – PARTICULARS OF THE ISSUE

OBJECTS OF THE ISSUE

Estimated fit-out cost, rental amounts, and security deposits

The fit-out cost, rental amounts, and security deposits are mentioned below:

Location	Sq.ft	Fit Out Cost (In Rs.)	Rental amount per month (In Rs.) [#]	Security Deposit*(In Rs.)
Vasai-Virar	1415 Sq.ft	56,60,000	2,54,700	15,28,200
Akola-Ozone Hospital	1600 Sq.ft	64,00,000	50,000 or 3% of Monthly Sales, whichever is higher	NIL
Akola-Noble Hospital	1400 Sq.ft	56,00,000	50,000 or 3% of Monthly Sales, whichever is higher	NIL
Malad-Kandivali	1500 Sq.ft	60,00,000	4,12,500	24,75,000
Kalyan	1700 Sq.ft	68,00,000	3,40,000	20,40,000
Total Cost		3,04,60,000		60,43,200

Notes: * Security Deposit are for 6 months

[#] For Malad-Kandivali Rs. 275 Per Sq. ft and for Kalyan Rs. 200 Per Sq. ft is assumed and for Vasai-Virar, Akola-Ozone Hospital, Akola-Noble Hospital as per MOU

The details of total cost is mentioned below:

Particulars	Amount (In Rs.)
Total Fit Out Cost	3,04,60,000
Total Security Deposit	60,43,200
Total Cost	3,65,03,200

As on March 31, 2025, the internal accruals available with company as per Restated Consolidated Financials is Rs. 492.95 Lakhs and Restated Standalone Financials is Rs. 522.74 Lakhs.

Government Approvals:

For details of laws applicable and approvals required for the Projects, see “Key Regulations and Policies” and “Government and Other Approvals” on pages 183 and 261 of the DRHP. Such approvals are granted only on establishment of a diagnostic centre, which include installation of medical devices such CT scanners and MRI machines. On completion, we will apply for such approvals in the ordinary course and in accordance with applicable laws.


Licenses required for setting up the new diagnostic centers in relation to the Objects of the Issue are mentioned below:

1. Certificate of Registration under Pre- Conception and Pre- Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 2003.
2. Registration for Operation of Medical Diagnostic X- Ray Equipment under Atomic Energy Act, 1962 read in conjunction with Rule (3) of the Atomic Energy (Radiation Protection) Rules {AE(RP)R}, 2004.
3. License for Operation of Nuclear Medical Facility (PET-CT) under Atomic Energy Act, 1962 read in conjunction with Rule (3) of the Atomic Energy (Radiation Protection) Rules {AE(RP)R}, 2004.
4. Combined Consent and Bio-Medical Waste Authorization (CCA) under the provisions of Water (P&CP) Act, 1974, Air (P&CP) Act, 1981, Environment (P) Act, 1986 and rules made there under including BMW Management Rules, 2016.
5. Certificate of Registration under Maharashtra Shops and Establishments (Regulation of Employment and Condition of Service) Act, 2017.”

SECTION VI – ABOUT THE COMPANY

OUR BUSINESS

Our Operational Network



Suppliers and Operational Procurement

Our key suppliers include a diverse range of leading multi-national equipment, instrument, reagent and film manufacturers, including some vendors who sell more than one range of products. We purchased basic and advanced radiology equipment and instruments from local suppliers. We own the radiology equipment and instruments and pathology equipment and instruments.

Further, our company follows a procurement process to ensure the availability of essential supplies required for its daily operations. For **FDG (Fluorodeoxyglucose)**, a radioactive tracer critical for PET/CT scans, the required quantity is estimated based on the number of scheduled appointments for the next day. Orders are placed with vendors to ensure early morning delivery, adhering to standard operating procedures and avoiding wastage due to the tracer's short half-life. **Contrast materials**, used in CT and MRI scans to enhance the visibility of internal structures, are procured periodically based on usage tracking and projected demand to maintain sufficient stock levels. Similarly, **medical films** for printing diagnostic images from X-rays, CT scans, and MRIs are monitored and replenished in a timely manner to prevent shortages and ensure operational efficiency. The procurement of **medical consumables** such as injections, needles, tubes, gels, sterile gloves, and sanitizers is managed through frequent inventory checks, ensuring adequate stock and compliance with safety standards. **Reagents**, which are crucial for conducting pathology tests, are procured in coordination with suppliers, taking into account consumption trends and expiration dates, thereby ensuring accuracy and reliability in test results. Additionally, **stationery and office supplies** like branded letterheads, envelopes, and bags are monitored at each centre, with orders placed as per actual usage to maintain optimal levels for operational and marketing needs.

This procurement system, with its focus on inventory monitoring, periodic replenishment, and supplier coordination, ensures that all necessary supplies are available across centres. It minimizes service interruptions, prevents overstocking or wastage, and supports smooth and efficient operations.

Our Customers

Institutional Business

The Institutional Business Clients and number of Patients Served under Institutional Business Client for periods indicated

provided by the company are mentioned below:

Based on Consolidated Basis:

Year	Number of Institutional Business Client	No. of Patients Served under Institutional Client
2024-25	106	5341
2023-24	89	1434

Based on Standalone Basis:

Year	Number of Institutional Business Client	No. of Patients Served under Institutional Client
2024-25	48	1,660
2023-24	55	1183
2022-23	24	363

As certified by M/s. Kanak Rathod & Co., Chartered Accountants, by way of their certificate dated August 01, 2025.

Human Resource

As of May 31, 2025, we have 108 full-time employees and 24 regular consultants on retainer basis and 20 Contractual employees, including 5 Key Managerial Personnel & Senior Management Personnel, 3 lab doctors, 19 radiologists and 125 technical staff and phlebotomists. Our laboratory is managed by qualified scientific staff and supervised by a team of pathologists with specializations in relevant fields of laboratory medicine. Our radiologists include professional who are well versed in their specialties, with numerous scientific publications, serve on committees of various Radiology societies and regularly present at national and international conferences.

The following table sets forth the number of our employees and consultants as of May 31, 2025:

Particulars	No. of Employees *
Key Management Personnel & Senior Management Personnel	5
Radiologists and laboratory doctors	22
Technical Staff	29
Sales and marketing	24
Support Staff	72
Total	152

*The below mentioned table reflects the breakup of human resource:

Type of Employees	No. of Employees
Full-time employees (including subsidiaries)	108
Consultants on a retainer basis employed by company directly (including subsidiaries)	24
Contractual employees (including subsidiaries)	20
Total	152

Details of Employees' Provident Fund and Employees State Insurance Corporation as on March 31, 2025:

Particulars	Number of employees registered*	Amount paid (₹ in lakhs)
Employees' Provident Fund	1	0.50
Employees State Insurance Corporation	N.A.	N.A.
Non EPF & ESIC	127	N.A.

Note: - Non EPF Employees whose salary are above 15000/- hence EPF not applicable.

**It includes Full-time employees and Contractual on a retainer basis employed by company directly (including subsidiaries)*

As certified by M/s. Kanak Rathod & Co., Chartered Accountants, by way of their certificate dated August 18, 2025.

We offer training to our staff on an ongoing basis and such training goes beyond the development of the required skills. This encompasses training on knowledge, skills and attitude. This approach ensures the deployment of competent staff to deliver quality service to our customers that earns the trust of not just our customers but the entire ecosystem of healthcare providers at large. Managerial and leadership trainings are also conducted to boost the development of the managerial competencies while building a leadership pipeline for our Company.

Properties

Details of our property are given below:

Sr No.	Location of the Properties ⁽¹⁾	Usage	Lessor	Lease tenure	Lease rent	Whether lessor is a related party	Lease deed is adequately stamped/ registered
1.	1 GF, Plot 217, Ambavat Bhavan, N.M Joshi Marg, Delisle Road, Mumbai – 400 013	Registered Office Laboratory and Spoke Centre	Chadraparakas h Bherulal Jain & Raju Bherulal Jain Sanghavi	July 01, 2025 to April 30, 2027	₹1.89 Lakhs p. m. for first 11 months. ₹2.04 Lakhs p. m. for next 11 months.	No	Registered Agreement
4.	Shop No. 7A & 7B, Vitthal Vinayak Sadan, A Wing, Plot 177, T.J. Road, Sewree, Mumbai – 400 015	Spoke Centre	Mr. Vijay Parshuram Adsule & Mrs. Vidya Vijay Adsule	July 27, 2025 to August 210, 2027	₹1.18 Lakhs p. m. for first 3 months. ₹1.24 Lakhs p. m. for next 12 months. ₹1.30 Lakhs p. m. for first 12 months.	No	Registered Agreement

SECTION VI – ABOUT THE COMPANY

OUR MANAGEMENT

Brief Profile of our Directors

Dr. Sanket Vinod Jain is the Chairman and Non-Executive Director on the Board of our Company. He holds the degree of M.B.B.S. from MGM Institute of Health Sciences and an M.D. (Radiodiagnosis) from Bharati Vidyapeeth Deemed University, Pune. He has approximately 6 years of experience as a consultant radiologist. He is associated as a consultant radiologist with one of our group companies, Primacare Healthcare LLP since 2019, and is also a consultant radiologist with our Company since 2021. He looks for performing and interpreting diagnostic imaging procedures, collaborating with physicians to develop treatment plans, and ensuring the accuracy and quality of radiology reports.

Changes to our Board in the last three years

Name	Designation (at the time of appointment / change in designation / cessation)	Date of appointment / change in designation / cessation	Reason
Rohit Prakash Srivastava	Managing Director	July 29, 2024	Resignation u/s 168 of the Companies Act, 2013 in order to focus on the role of CFO

Note: This table does not include details of regularisations of Additional Directors.

Changes in the Key Managerial Personnel or the Senior Management in last three years

Except as mentioned below, and as specified in “– *Changes to our Board in the last three years*” on page 206 of the DRHP, there have been no changes in the Key Managerial Personnel or Senior Management during the preceding three years:

Name	Date of Change	Reason for Change
Rohit Prakash Srivastava	July 29, 2024	Resignation as Managing Director u/s 168 of the Companies Act, 2013 to focus on the role of CFO.
Dr. Rahul Jain	February 01, 2025	Resignation as Senior Management Personnel continues with the Company in professional capacity as Pathologist.
Dr. Hrudendukumar Rasanand Patnaik	March 01, 2025	Resigned as Senior Management Personnel in order to pursue enhanced professional opportunities and career advancement elsewhere

SECTION VIII – LEGAL AND OTHER INFORMATION

OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS

Litigation involving our Promoters

A. Litigation Against Our Promoters

(iv) Claims related to direct and indirect taxes

a. Direct Tax

As per website of Income Tax, the following e-proceedings are shown as pending with “open” or “pending” status. However, the amount has not been mentioned and cannot be crystallized:

• E- Proceedings:

Assessment Year	Proceeding Name	Amount	Proceeding Status
Ketan Jayantilal Jain			
2020-2021	An Issue Letter was issued against our Promoter under Section 211 of the Income Tax Act, 1961 vide DIN & Letter No: ITBA/COM/F/17/2019-20/1025825726(1) dated February 27, 2020, regarding computation of total tax liability and payment of advance tax for FY 2019-2020. Mr. Ketan Jayantilal Jain has paid the income tax for AY 2020-21. The said issue letter was compiled and no new notice have been received as on date.	Nil	NA

SECTION X - OTHER REGULATORY AND STATUTORY DISCLOSURES

Eligibility for the Issue

As Per Restated Consolidated Financial Information:

(in ₹ Lakhs)

Particulars	March 31, 2025	March 31, 2024
Cash flow from Operations (I)	655.86	636.16
Purchase of Fixed Assets (II)	(37.20)	(847.77)
Net Borrowings (III)	(27.30)	380.14
Interest x (1-T) (IV)	(17.29)	(7.49)
FCFE* (V) (I - II + III - IV)	574.07	161.04

As certified by M/s RSAV & Company, Chartered Accountants by way of their certificate dated August 01, 2025

As Per Restated Standalone Financial Information:

(in ₹ Lakhs)

Particulars	March 31, 2025	March 31, 2024	March 31, 2023
Cash flow from Operations (I)	278.84	331.11	169.73
Purchase of Fixed Assets (II)	(21.00)	(45.37)	(8.74)
Net Borrowings (III)	(8.64)	193.55	(39.00)
Interest x (1-T) (IV)	(2.60)	(2.55)	(1.51)
FCFE* (V) (I - II + III - IV)	246.60	476.74	120.48

As certified by M/s RSAV & Company, Chartered Accountants by way of their certificate dated August 01, 2025